 Innate Pharma SA NASDAQ: IPHA has announced preliminary data from the mycosis fungoides MF cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab. Data were shared at the International Conference on Malignant Lymphoma. 